Web Analytics
TDM1 Approval Expanded for HER2Positive Breast Cancer Tees 4

TDM1 Approval Expanded for HER2Positive Breast Cancer Tees 4


An illustration showing how T-DM1 works to kill cancer cells

The statistical design assumed an -improvement of 25% with T-DM1. The efficacy stopping boundary for the single, prespecified boundary for early reporting ...

... Download full-size image

Download figure ...

Tucatinib is a HER2-selective tyrosine kinase inhibitor. As an oral agent, tucatinib may be associated with fewer side effects than other such inhibitors.

... Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine ( T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting

Download figure ...

1: Treatment approach for patient presenting with HER2-positive metastatic breast cancer in 2013. Courtesy of Eric P. Winer, MD.

Expression of CTLA-4, PD-1, and PD-L1 and combination therapy of T-DM1... | Download Scientific Diagram

T-DM1 selectively delivers DM1 to HER2-positive ...

T-DM1 blocks the immune-mediated enrichment of CD44highCD24low and ALDH+ breast cancer CSCs

Preferential targeting of clonogenic breast cancer cells by T-DM1. (a) HER2-positive breast cancer cells (left: SK-BR-3, right: BT-474) were treated for 48 ...

Table 3 Ongoing clinical trials of peptide- and DC-based vaccine immunotherapeutics in breast cancer

Figure 1

Download figure ...

Figure 1

CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast ...

Refining Current Treatments and Looking Ahead in HER2-positive Breast Cancer

During coculture with NK cells, T-DM1 can induce ADCC in breast cancer... | Download Scientific Diagram

Download figure ...

Ado-trastuzumab Emtansine a Potential New Treatment Option for HER2-Amplified Advanced Salivary Gland Cancer

Acquired T-DM1 resistance is characterized by loss of T-DM1-induced mitotic arrest, apoptosis and DNA damage in HER2-positive breast cancer. a Dose–response ...

Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer

Effectors of EGFR/HER2 downstream signaling pathways and corresponding effective potential clinical drugs. ATA, acetyltanshinone IIA; AE, aloe-emodin; ...

Download figure ...

Frontiers | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy | Immunology


Kadcyla was approved by the U.S. Food and Drug Administration in February of 2013.

Digital Object Thumbnail QUICK TAKE Trastuzumab Emtansine in Residual Breast Cancer

Breast cancer drug that can extend lives approved for NHS use | Society | The Guardian

Download figure ...

Among female patients with CML, fertility preservation with ovarian stimulation can be challenging i

Pretreatment with trastuzumab in HER-2-positive cells up-regulated caveolin-1 expression and improved T-DM1 drug efficacy. (A) Treatment of BT-474 cells ...

About one-third of patients will experience disease recurrence after undergoing nephrectomy, and cli

... type #HER2 and the variant d16her2 in tumor context of multiple cancer types #breastcancer @SciReports http://bit.ly/2WnF7Rl pic.twitter.com/DRSqgQiAXu

DRUGS used for Her 2 neu + Breast Cancer Brand Name Generic name. Taxol = paclitaxel. Taxotere = docetaxol. Xeloda = capecitabine


Daiichi Sankyo

Figure 1. Timeline of FDA approvals of HER2-targeted breast cancer ...

Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches - Oncology Nurse Advisor


Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations

Basal-HER2+ BC cells accumulate a majority of the known mechanisms for trastuzumab resistance,

New Trends in Pre-Surgery Treatments for Breast Cancer. October 4 ...

In vitro efficacy of T-DM1 combined with pertuzumab on cell proliferation and apoptosis. (a and c) Inhibition of cell growth induced by pertuzumab (40 ...

Sign in to download full-size image

In a case report of a previously treated patient with NSCLC harboring an exon 20 HER2 mutation, off-label use of afatinib therapy was administered.

Updated NCCN Breast Cancer Guidelines

Trastuzumab emtansine (T-DM1) is currently approved for the treatment of patients with HER2-positive metastatic breast cancer after failure of prior ...

[Fam-] Trastuzumab Deruxtecan Demonstrates Encouraging Responses in Advanced HER2+ Breast Cancer

A Record Number of Anticancer Indications Approved by the FDA in 2017

Cancers 11 00394 g001 550

View in gallery

[Abstract in Chinese]. Introduction. Breast cancer ...

Tees 4 Cancer · Vaccine to Treat Lymphoma Advancing in Trials , #

Click here to view

Why You Need to Know Your HER2 Results if You Have Breast Cancer

A reclassification of cHER2+ tumors based on basal (e.g.,

View in gallery NCCN Guidelines Insights: Breast Cancer ...

Download figure ...

Download figure ...

In HER2-Negative Breast Cancer, Brain Mets Are HER2-Positive 20% of Time

... Download full-size image

Encouraging Results for [Fam-] Trastuzumab Deruxtecan in HER2 Expressing Advanced Colorectal Cancer

HER2-Positive Metastatic Breast Cancer. her2, metastatic, breast

Kadcyla or T-DM1 Breast Cancer Drug


Vik Gorantla, MD Vik Gorantla, MD. The outlook for HER2-positive breast cancer ...

4 replies 13 retweets 25 likes

Download high-res image ...

Structure of trastuzumab emtansine and mechanisms of action. Notes: On binding of trastuzumab emtansine

Tees 4 Cancer · Improving Quality of Cancer Research Biopsy Specimens , #


Figure 1

Page 1

genentech submits supplemental biologics license application to fda for kadcyla for adjuvant treatment of people with

... Download full-size image. Fig. 1. Current advanced HER2-positive breast cancer ...

Download figure ...

Because trastuzumab-refractory CD44+CD24

Download high-res image ...

Clinical trials of pertuzumab-based and ado-TrastuzumabEmtansine therapy for the treatment of HER2-overexpressing advanced or metastatic gastric cancer.

ASCO 2017 Abstract 507; 40. • HER2-positive (HER2+) breast cancer ...

Figure 4

Table 3 Pivotal undergoing clinical trials of ribociclib or LEE011 for the treatment of various cancers (www.clinicaltrials.gov)

Figure 2 Dermoscopy image of one of the lesions, showing expanded branching vessels

OncLive: What are some of the key takeaways from your discussion of the evolving treatment landscape in HER2-positive breast cancer?

Inhibition of HER2-signal transduction after the triple-drug treatment. Lysates from tumor tissues collected 4 days after starting treatment were used for ...

... tshirt

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Chart of the Herceptin Adjuvant (HERA) Trial.

Community Practice Connections™: Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer

Breast Cancer Treatment

Thumbnail of the PDF version of Treatment Update: Breast Cancer With Highlights from the 2018

4 HER2-Positive Breast Cancer: Introduction

Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine

EMA Recommends Approval of Four New Anticancer Agents in September

... Download full-size image

Figure B1-3: When considering the activity of trastuzumab in each type of bulk

T-DM1 May Allow Chemotherapy De-escalation in Neoadjuvant and Adjuvant HER2- Positive Primary Breast Cancer